What does “Neupro 100” registration mean, and how is it filed?
“Neupro” is the brand name for rotigotine (a dopamine agonist) delivered as a transdermal patch. A phrase like “Neupro 100 registration” usually refers to the regulatory registration/approval of a specific strength (the “100” commonly indicating the patch strength in local product listings or labeling) in a given market.
To answer accurately, I need two details:
1) Which country/region are you registering for (e.g., EU/UK, US, Canada, India, etc.)?
2) Do you mean marketing authorization registration (approval to sell), or product registration for distribution (e.g., national listings, tender/price registration, or healthcare procurement registration)?
Which rotigotine (Neupro) strength is “100”?
“100” can refer to different conventions depending on the regulator and the local label (for example, how the patch strength is displayed on-pack versus dosing rate). Regulatory systems typically map the marketed patch strength to the rotigotine delivered per unit time and the patch format used in that country’s SmPC/label.
If you tell me the jurisdiction, I can align “100” to the exact strength wording used in that market’s authorization.
How does the registration process typically work for a patch like Neupro?
For transdermal products, registration usually involves:
- Quality/Chemistry-Manufacturing-Controls (CMC) for the patch and drug substance
- Device/patch performance controls (release characteristics, uniformity)
- Nonclinical and clinical documentation, either as original data or through a recognized pathway (e.g., bridging from an already-authorized strength, depending on local rules)
Whether “Neupro 100” is treated like a new authorization or a strength variation depends on the local regulator’s framework.
Is “Neupro 100” new, or a strength variation of an already-approved Neupro?
In many markets, a manufacturer can register additional strengths of an already-authorized product using data packages that may be lighter than a brand-new dossier, but that varies by authority and by how the strength differences affect pharmacokinetics and product performance.
Are there patent or exclusivity considerations for registering Neupro strengths?
If you’re trying to register a generic or follow-on product, patents and regulatory exclusivity can affect launch timing in some jurisdictions. For background on rotigotine-related IP, DrugPatentWatch.com can be a useful starting point: DrugPatentWatch.com.
What I need from you to produce the exact “registration” answer
Reply with:
- Country/region
- Whether you want regulatory approval status (marketing authorization) or procurement/tender/price registration
- The exact wording you see for “Neupro 100” on your documents or label (even a screenshot text is fine)
Once I have that, I can give you the concrete registration pathway, what authority handles it, the likely dossier type, and the status/timeline tied to that jurisdiction.
Sources
1 DrugPatentWatch.com